Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer
Tóm tắt
MMP and TIMP play an important role in the degradation of extracellular matrix components which are essential for tumor growth, invasion and metastasis. Aim of this research was to assess MMP3 and TIMP3 as prognostic factors among patients with ovarian cancer. It was found that high levels of output MMP3 correlated with shortened overall survival time of patients by 9.7 months. In addition, it has been shown that high concentrations of output MMP3 were significantly associated with a shorter disease free time in median concentrations implemented p = 0.0059. Statistically significant dependence has been shown between an average concentration of TIMP3 protein to the overall survival of patients. The higher output concentration of TIMP3, the longer patients’ survival by 8.9 month. In addition, it was found that high TIMP3 concentrations output were associated with a significantly longer disease free duration at a median concentrations p = 0.007. Preliminary research shows that output levels of MMP3 and TIMP3 proteins correlate with overall survival of patients. In some cases also time free of illness.
Tài liệu tham khảo
van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Neijt JP. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol. 1989;7(6):769–73.
Hoskins P, Tu D, James K, Pater J, Koski B. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups. Gynecol Oncol. 1998;70(2):224–30.
Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JFA. prognostic model for ovarian cancer. Br J Cancer. 2001;85(7):944–52.
van Meurs HS, Schuit E, Horlings HM, van der Velden J, van Driel WJ, Mol BW, et al. Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary. Gynecol Oncol. 2014;134(3):498–504.
Zhang C, Li C, Zhu M, Zhang Q, Xie Z, Niu G, et al. Meta-analysis of MMP2, MMP3, and MMP9 promoter polymorphisms and head and neck cancer risk. PLoS One. 2013;8(4):e62023.
Wei SU, Li H, Zhang B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomed Rep. 2016;5(1):41–4.
Chudecka-Glaz A, Cymbaluk-Ploska A, Luterek-Puszynska K, Menkiszak J. Diagnostic usefulness of the risk of ovarian malignancy algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125. Oncol Lett. 2016;12(5):3101–14.
Pelissier A, Bonneau C, Chereau E, DE LA Motte Rouge T, Fourchotte V, Darai E, et al. Dynamic analysis of CA125 decline during Neoadjuvant chemotherapy in patients with epithelial ovarian cancer as a predictor for platinum sensitivity. Anticancer Res. 2016;36(4):1865–71.
Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer. Onkologie. 2008;31(6):315–20.
Trudel D, Tetu B, Gregoire J, Plante M, Renaud MC, Bachvarov D, et al. Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol. 2012;127(3):511–5.
Piovano E, Attamante L, Macchi C, Cavallero C, Romagnolo C, Maggino T, et al. The role of HE4 in ovarian cancer follow-up: a review. Int J Gynecol Cancer. 2014;24(8):1359–65.
Cymbaluk-Ploska A, Chudecka-Glaz A, Surowiec A, Pius-Sadowska E, Machalinski B, Menkiszak J. MMP3 in comparison to CA 125, HE4 and the ROMA algorithm in differentiation of ovarian tumors. Asian Pac J Cancer Prev. 2016;17(5):2597–603.
Herszenyi L, Hritz I, Lakatos G, Varga MZ, Tulassay Z. The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer. Int J Mol Sci. 2012;13(10):13240–63.
Baruch RR, Melinscak H, Lo J, Liu Y, Yeung O, Hurta RA. Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation. Cell Biol Int. 2001;25(5):411–20.
Choi JW, Ahn SE, Rengaraj D, Seo HW, Lim W, Song G, et al. Matrix metalloproteinase 3 is a stromal marker for chicken ovarian cancer. Oncol Lett. 2011;2(6):1047–51.
Denys H, Braems G, Lambein K, Pauwels P, Hendrix A, De Boeck A, et al. The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment. Curr Pharm Des. 2009;15(12):1373–84.
Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U, Uray M. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol. 2003;24(5):417–20.
Hu X, Li D, Zhang W, Zhou J, Tang B, Li L. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch Gynecol Obstet. 2012;286(6):1537–43.
Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer. 2003;39(13):1948–56.
Desmeules P, Trudel D, Turcotte S, Sirois J, Plante M, Gregoire J, et al. Prognostic significance of TIMP-2, MMP-2, and MMP-9 on high-grade serous ovarian carcinoma using digital image analysis. Hum Pathol. 2015;46(5):739–45.
Qi JH, Anand-Apte B. Tissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism. Apoptosis. 2015;20(4):523–34.
Das AM, Koljenovic S, Oude Ophuis CM, van der Klok T, Galjart B, Nigg AL, et al. Association of TIMP3 expression with vessel density, macrophage infiltration and prognosis in human malignant melanoma. Eur J Cancer. 2016;53:135–43.
Gu X, Fu M, Ding Y, Ni H, Zhang W, Zhu Y, et al. TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC. PLoS One. 2014;9(8):e106161.
Brun JL, Cortez A, Lesieur B, Uzan S, Rouzier R, Darai E. Expression of MMP-2, −7, −9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer. Oncol Rep. 2012;27(4):1049–57.
Kang WD, Choi HS, Kim SM. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer. Gynecol Oncol. 2010;116(1):57–60.